Teva Pharmaceuticals has agreed to pay $35 million to resolve a class action lawsuit alleging it engaged in anticompetitive conduct to block generic competition for its QVAR and QVAR RediHaler asthma inhalers, keeping prices artificially high for consumers.
The lawsuit claims Teva illegally sought to prevent cheaper generic alternatives from entering the market, forcing consumers and their insurers to pay inflated prices for QVAR products.
Who Qualifies?
You may be eligible if you purchased, paid for, or provided reimbursement for QVAR® or QVAR RediHaler® inhalers between January 1, 2015 and July 31, 2025 in one of the 42 eligible states plus Washington, D.C.
How Much Can You Receive?
The exact payment amount is not yet determined and will depend on the number of products purchased and total number of valid claims filed. Payments will be distributed pro rata from the $35 million net settlement fund.
Claim deadline: July 31, 2026